In surgical settings, managing von Willebrand disease (VWD) often requires von Willebrand factor (VWF) concentrate administration, and close monitoring of factor VIII (FVIII) and VWF to balance bleeding...
Lire la suite

Von Willebrand Disease (VWD), the most common inheritedbleeding disorder, disproportionately affects women due togynecological hemostatic challenges such as menstruation andchildbirths [1, 2]. Heavy menstrual...
Lire la suite

Type 2B von Willebrand disease (VWD) is a rare qualitative variant, accounting for ∼5% of all VWD cases. It is characterized by increased affinity of abnormal von Willebrand factor (VWF) for the platelet...
Lire la suite

Hemophilia A (HA) management has progressed significantly, yet standard and extended half-life (EHL) clotting factors present persistent limitations, including intravenous burden and suboptimal trough levels. This narrative review highlights recently approved agents and phase III candidates for HA. In replacement therapy, efanesoctocog alfa maintains normal-to-near-normal factor VIII (FVIII) levels weekly by bypassing endogenous von Willebrand factor...
Lire la suite